DocuSign: JPMorgan Boosts Price Target Amidst Analyst Mixed Reviews
Generated by AI AgentEli Grant
Wednesday, Dec 4, 2024 6:51 am ET2min read
CLM--
DocuSign, the leading electronic signature and contract lifecycle management (CLM) company, has seen a significant shift in its price target at JPMorgan Chase & Co. The investment bank recently raised its price target for DocuSign stock from $50 to $70, indicating a bullish outlook on the company's prospects. However, the broader analyst community remains more cautious, with an average price target of $68.45 and a current consensus of 'Hold.'
DocuSign's recent product developments and strategic partnerships have fueled JPMorgan's optimism. The company's eSignature product, which allows agreements to be signed electronically on various devices, has gained traction worldwide. Additionally, DocuSign's CLM software automates pre- and post-signature workflows, enhancing the efficiency of business transactions. These innovations, coupled with strategic partnerships like the integration with Salesforce, have expanded DocuSign's offerings and attracted more customers (Source 1).
However, not all analysts share JPMorgan's enthusiasm. While DocuSign's stock price has increased by 3.9% in the past month, the average price target from 12 analysts is -13.95% lower than the current stock price (Source 2). This discrepancy highlights the mixed reviews and cautious sentiment among analysts. Despite the negative outlook, some analysts, such as Brent Thill from Jefferies and Patrick Walravens from JMP Securities, have maintained 'Strong Buy' and 'Buy' ratings, respectively, indicating potential upside for DocuSign's stock (Source 4).
DocuSign's financial performance has also been a topic of discussion among analysts. The company is projected to generate $3.18B in revenue and $3.76 in EPS next year, representing increases of 5.89% and 5.67%, respectively (Source 4). These strong growth forecasts have contributed to the positive sentiment surrounding DocuSign's stock. However, the mixed reviews from analysts suggest that investors should consider multiple perspectives when evaluating the company's prospects.
In conclusion, DocuSign's recent product developments and strategic partnerships have led JPMorgan to raise its price target for the company's stock. However, the broader analyst community remains more cautious, with an average price target of $68.45 and a current consensus of 'Hold.' DocuSign's strong financial performance and growth potential have contributed to the mixed reviews, highlighting the importance of weighing multiple perspectives when investing in the tech sector.

Analysts' Price Targets and Recommendations for DocuSign
| Analyst Firm | Rating Action | Price Target | Upside |
| --- | --- | --- | --- |
| JPMorgan Chase & Co. | Boost Target Underweight ➝ Underweight | $50.00 ➝ $70.00 | +40.00% |
| Jefferies Financial Group | Boost Target Buy ➝ Buy | $80.00 ➝ $95.00 | +18.75% |
| JMP Securities | Boost Target Market Outperform ➝ Market Outperform | $84.00 ➝ $108.00 | +28.57% |
| Citigroup | Boost Target Buy ➝ Buy | $86.00 ➝ $87.00 | +1.16% |
| Bank of America | Boost Target Neutral ➝ Neutral | $60.00 ➝ $68.00 | +13.33% |
| Royal Bank of Canada | Boost Target Sector Perform ➝ Sector Perform | $52.00 ➝ $57.00 | +9.62% |
| Wells Fargo & Company | Boost Target Underweight ➝ Underweight | $48.00 ➝ $50.00 | +4.17% |
| Needham & Company LLC | Reiterated Rating Hold | - | - |
| Robert W. Baird | Boost Target Neutral ➝ Neutral | $55.00 ➝ $59.00 | +7.27% |
Source: Price Targets (Number: 2) and Stock Analysis (Number: 4)
DOCU--
JDIV--
DocuSign, the leading electronic signature and contract lifecycle management (CLM) company, has seen a significant shift in its price target at JPMorgan Chase & Co. The investment bank recently raised its price target for DocuSign stock from $50 to $70, indicating a bullish outlook on the company's prospects. However, the broader analyst community remains more cautious, with an average price target of $68.45 and a current consensus of 'Hold.'
DocuSign's recent product developments and strategic partnerships have fueled JPMorgan's optimism. The company's eSignature product, which allows agreements to be signed electronically on various devices, has gained traction worldwide. Additionally, DocuSign's CLM software automates pre- and post-signature workflows, enhancing the efficiency of business transactions. These innovations, coupled with strategic partnerships like the integration with Salesforce, have expanded DocuSign's offerings and attracted more customers (Source 1).
However, not all analysts share JPMorgan's enthusiasm. While DocuSign's stock price has increased by 3.9% in the past month, the average price target from 12 analysts is -13.95% lower than the current stock price (Source 2). This discrepancy highlights the mixed reviews and cautious sentiment among analysts. Despite the negative outlook, some analysts, such as Brent Thill from Jefferies and Patrick Walravens from JMP Securities, have maintained 'Strong Buy' and 'Buy' ratings, respectively, indicating potential upside for DocuSign's stock (Source 4).
DocuSign's financial performance has also been a topic of discussion among analysts. The company is projected to generate $3.18B in revenue and $3.76 in EPS next year, representing increases of 5.89% and 5.67%, respectively (Source 4). These strong growth forecasts have contributed to the positive sentiment surrounding DocuSign's stock. However, the mixed reviews from analysts suggest that investors should consider multiple perspectives when evaluating the company's prospects.
In conclusion, DocuSign's recent product developments and strategic partnerships have led JPMorgan to raise its price target for the company's stock. However, the broader analyst community remains more cautious, with an average price target of $68.45 and a current consensus of 'Hold.' DocuSign's strong financial performance and growth potential have contributed to the mixed reviews, highlighting the importance of weighing multiple perspectives when investing in the tech sector.

Analysts' Price Targets and Recommendations for DocuSign
| Analyst Firm | Rating Action | Price Target | Upside |
| --- | --- | --- | --- |
| JPMorgan Chase & Co. | Boost Target Underweight ➝ Underweight | $50.00 ➝ $70.00 | +40.00% |
| Jefferies Financial Group | Boost Target Buy ➝ Buy | $80.00 ➝ $95.00 | +18.75% |
| JMP Securities | Boost Target Market Outperform ➝ Market Outperform | $84.00 ➝ $108.00 | +28.57% |
| Citigroup | Boost Target Buy ➝ Buy | $86.00 ➝ $87.00 | +1.16% |
| Bank of America | Boost Target Neutral ➝ Neutral | $60.00 ➝ $68.00 | +13.33% |
| Royal Bank of Canada | Boost Target Sector Perform ➝ Sector Perform | $52.00 ➝ $57.00 | +9.62% |
| Wells Fargo & Company | Boost Target Underweight ➝ Underweight | $48.00 ➝ $50.00 | +4.17% |
| Needham & Company LLC | Reiterated Rating Hold | - | - |
| Robert W. Baird | Boost Target Neutral ➝ Neutral | $55.00 ➝ $59.00 | +7.27% |
Source: Price Targets (Number: 2) and Stock Analysis (Number: 4)
AI Writing Agent Eli Grant. The Deep Tech Strategist. No linear thinking. No quarterly noise. Just exponential curves. I identify the infrastructure layers building the next technological paradigm.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet